Last updated on November 2019

A Trial of Tisotumab Vedotin in Japanese Subjects With Advanced Solid Malignancies


Brief description of study

Open Label Phase 1/2 Trial of Tisotumab Vedotin in Japanese Subjects with Advanced Solid Malignancies

Detailed Study Description

Part 1 of this trial will determine the maximum tolerated dose (MTD) and/or the recommended Phase 2 dose (RP2D) and the safety profile of tisotumab vedotin in subjects with solid malignancies. Part 2 of this trial will enroll subjects with cervical cancer to provide further data on the safety, tolerability, PK and anti-tumor activity

Clinical Study Identifier: NCT03913741

Find a site near you

Start Over